Stock analysts at Cantor Fitzgerald assumed coverage on shares of Aduro BioTech (NASDAQ:ADRO) in a research report issued to clients and investors on Wednesday. The firm set an “overweight” rating and a $15.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 145.90% from the company’s current price.
ADRO has been the topic of a number of other research reports. BidaskClub upgraded shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 23rd. HC Wainwright set a $18.00 target price on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Wednesday, November 1st. Oppenheimer started coverage on shares of Aduro BioTech in a research note on Monday, October 30th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, ValuEngine lowered shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $17.38.
Shares of Aduro BioTech (NASDAQ:ADRO) opened at $6.10 on Wednesday. Aduro BioTech has a 12 month low of $5.82 and a 12 month high of $14.05.
In related news, EVP Dirk G. Brockstedt sold 65,223 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $8.11, for a total transaction of $528,958.53. Following the completion of the sale, the executive vice president now owns 137,826 shares of the company’s stock, valued at approximately $1,117,768.86. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Jennifer Lew sold 6,600 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $9.46, for a total transaction of $62,436.00. Following the sale, the vice president now directly owns 68,938 shares of the company’s stock, valued at approximately $652,153.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 172,656 shares of company stock valued at $1,486,582. Insiders own 6.60% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Fox Run Management L.L.C. bought a new stake in shares of Aduro BioTech during the 3rd quarter valued at about $127,000. SG Americas Securities LLC bought a new position in Aduro BioTech in the 3rd quarter worth about $167,000. Trexquant Investment LP bought a new position in Aduro BioTech in the 3rd quarter worth about $175,000. MetLife Investment Advisors LLC bought a new position in Aduro BioTech in the 4th quarter worth about $140,000. Finally, Voya Investment Management LLC grew its position in Aduro BioTech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 2,515 shares during the last quarter. 42.61% of the stock is owned by institutional investors and hedge funds.
WARNING: “Cantor Fitzgerald Begins Coverage on Aduro BioTech (ADRO)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/22/aduro-biotech-adro-receives-new-coverage-from-analysts-at-cantor-fitzgerald.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.